Elevated levels of several chemokines in the cerebrospinal fluid of patients with subarachnoid hemorrhage are associated with worse clinical outcome.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 12 06 2022
accepted: 14 02 2023
entrez: 9 3 2023
pubmed: 10 3 2023
medline: 14 3 2023
Statut: epublish

Résumé

Chemokines are small cytokines that exert chemotactic actions on immune cells and are involved in many inflammatory processes. The present study aims to provide insight in the role of this relatively unexplored family of proteins in the inflammatory pathophysiology of subarachnoid hemorrhage (SAH). Cerebrospinal fluid of 29 patients (17 female; mean age 57 years) was collected at days 1, 4 and 10 after SAH, centrifuged and frozen at -70°C. Analysis of 92 inflammation-related proteins was performed using Target 96 Inflammation ® assay (Olink Proteomics, Uppsala, Sweden) based on Proximity Extension Assay technology. The panel included 20 chemokines (CCL2 (or MCP-1), CCL3, CCL4, CCL7 (or MCP-3), CCL8 (or MCP-2), CCL11 (or Eotaxin), CCL13 (or MCP-4), CCL19, CCL20, CCL23, CCL25, CCL28, CXCL1, CXCL5, CXCL6, CXCL8 (or IL-8), CXCL9, CXCL10, CXCL11 and CX3CL1 (or Fractalkine)) that were analyzed for their temporal patterns of expression and compared in dichotomized clinical groups based on World Federation of Neurosurgical Societies (WFNS) admission score and amount of blood on admission CT based on Fisher scale; presence of delayed cerebral ischemia(DCI)/delayed ischemic neurological deficit (DIND); and clinical outcome based on Glasgow Outcome Scale. Protein expression levels were provided in output unit Normalized Protein Expression (NPX). ANOVA models were used for statistical analyses. Four temporal patterns of expression were observed (i.e., early, middle, late peak and no peak). Significantly higher day 10 mean NPX values were observed in patients with poor outcome (GOS 1-3) for chemokines CCL2, CCL4, CCL7, CCL11, CCL13, CCL19, CCL20, CXCL1, CXCL5, CXCL6 and CXCL8. In the WFNS 4-5 group, CCL11 showed significantly higher day 4 and day 10 mean NPX values and CCL25 significantly higher day 4 values. In patients with SAH Fisher 4, CCL11 showed significantly higher mean NPX values on days 1, 4 and 10. Finally, patients with DCI/DIND had significantly higher day 4 mean NPX values of CXCL5. Higher levels of multiple chemokines at the late stage of SAH seemed to correlate with worse clinical outcome. A few chemokines correlated with WFNS score, Fisher score and occurrence of DCI/DIND. Chemokines may be useful as biomarkers for describing the pathophysiology and prognosis of SAH. Further studies are needed to better understand their exact mechanism of action in the inflammatory cascade.

Sections du résumé

BACKGROUND
Chemokines are small cytokines that exert chemotactic actions on immune cells and are involved in many inflammatory processes. The present study aims to provide insight in the role of this relatively unexplored family of proteins in the inflammatory pathophysiology of subarachnoid hemorrhage (SAH).
MATERIALS AND METHODS
Cerebrospinal fluid of 29 patients (17 female; mean age 57 years) was collected at days 1, 4 and 10 after SAH, centrifuged and frozen at -70°C. Analysis of 92 inflammation-related proteins was performed using Target 96 Inflammation ® assay (Olink Proteomics, Uppsala, Sweden) based on Proximity Extension Assay technology. The panel included 20 chemokines (CCL2 (or MCP-1), CCL3, CCL4, CCL7 (or MCP-3), CCL8 (or MCP-2), CCL11 (or Eotaxin), CCL13 (or MCP-4), CCL19, CCL20, CCL23, CCL25, CCL28, CXCL1, CXCL5, CXCL6, CXCL8 (or IL-8), CXCL9, CXCL10, CXCL11 and CX3CL1 (or Fractalkine)) that were analyzed for their temporal patterns of expression and compared in dichotomized clinical groups based on World Federation of Neurosurgical Societies (WFNS) admission score and amount of blood on admission CT based on Fisher scale; presence of delayed cerebral ischemia(DCI)/delayed ischemic neurological deficit (DIND); and clinical outcome based on Glasgow Outcome Scale. Protein expression levels were provided in output unit Normalized Protein Expression (NPX). ANOVA models were used for statistical analyses.
RESULTS
Four temporal patterns of expression were observed (i.e., early, middle, late peak and no peak). Significantly higher day 10 mean NPX values were observed in patients with poor outcome (GOS 1-3) for chemokines CCL2, CCL4, CCL7, CCL11, CCL13, CCL19, CCL20, CXCL1, CXCL5, CXCL6 and CXCL8. In the WFNS 4-5 group, CCL11 showed significantly higher day 4 and day 10 mean NPX values and CCL25 significantly higher day 4 values. In patients with SAH Fisher 4, CCL11 showed significantly higher mean NPX values on days 1, 4 and 10. Finally, patients with DCI/DIND had significantly higher day 4 mean NPX values of CXCL5.
CONCLUSION
Higher levels of multiple chemokines at the late stage of SAH seemed to correlate with worse clinical outcome. A few chemokines correlated with WFNS score, Fisher score and occurrence of DCI/DIND. Chemokines may be useful as biomarkers for describing the pathophysiology and prognosis of SAH. Further studies are needed to better understand their exact mechanism of action in the inflammatory cascade.

Identifiants

pubmed: 36893189
doi: 10.1371/journal.pone.0282424
pii: PONE-D-22-16901
pmc: PMC9997919
doi:

Substances chimiques

Chemokines 0
Cytokines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0282424

Informations de copyright

Copyright: © 2023 Vlachogiannis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Neurol Res. 1998 Jun;20(4):337-42
pubmed: 9618698
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Mol Neurobiol. 2011 Feb;43(1):27-40
pubmed: 21161614
Cell Mol Immunol. 2018 Apr;15(4):324-334
pubmed: 29375126
J Neuroinflammation. 2020 Jul 14;17(1):209
pubmed: 32664984
Front Neurol. 2017 Aug 08;8:379
pubmed: 28848487
Acta Neurochir Suppl. 2011;110(Pt 1):191-6
pubmed: 21116938
Transl Stroke Res. 2013 Aug;4(4):432-46
pubmed: 23894255
Lancet. 1975 Mar 1;1(7905):480-4
pubmed: 46957
Curr Neuropharmacol. 2018;16(9):1385-1395
pubmed: 29651951
Biomol Detect Quantif. 2015 May 20;4:10-6
pubmed: 27077033
Neurology. 2017 Apr 18;88(16):1535-1545
pubmed: 28314864
Int J Mol Sci. 2016 Apr 02;17(4):497
pubmed: 27049383
Neurol Res. 2009 Mar;31(2):151-8
pubmed: 19298755
Neurotherapeutics. 2020 Apr;17(2):436-445
pubmed: 31907877
Lancet. 2017 Feb 11;389(10069):655-666
pubmed: 27637674
J Neurosurg. 2008 Jul;109(1):38-43
pubmed: 18593272
J Neuroimmunol. 2021 Aug 15;357:577610
pubmed: 34030107
J Neurol Sci. 2016 Mar 15;362:53-8
pubmed: 26944117
J Neuroinflammation. 2016 Aug 30;13(1):217
pubmed: 27576738
Transl Stroke Res. 2020 Dec;11(6):1348-1361
pubmed: 31858408
J Neurol Neurosurg Psychiatry. 1988 Nov;51(11):1457
pubmed: 3236024
Neurocrit Care. 2009 Dec;11(3):362-8
pubmed: 19777384
Cytokine. 2020 Sep;133:155142
pubmed: 32485621
World Neurosurg. 2019 Aug;128:e1131-e1136
pubmed: 31121365
Neurocrit Care. 2019 Oct;31(2):373-389
pubmed: 31012056
J Neuroinflammation. 2019 Nov 11;16(1):213
pubmed: 31711504
Cytokine. 2019 Nov;123:154778
pubmed: 31323526
Neurosurgery. 1980 Jan;6(1):1-9
pubmed: 7354892
PLoS One. 2022 Mar 24;17(3):e0263460
pubmed: 35324941
N Engl J Med. 2017 Jul 20;377(3):257-266
pubmed: 28723321

Auteurs

Pavlos Vlachogiannis (P)

Department of Medical Sciences/Section of Neurosurgery, Uppsala University, Uppsala, Sweden.

Lars Hillered (L)

Department of Medical Sciences/Section of Neurosurgery, Uppsala University, Uppsala, Sweden.

Per Enblad (P)

Department of Medical Sciences/Section of Neurosurgery, Uppsala University, Uppsala, Sweden.

Elisabeth Ronne-Engström (E)

Department of Medical Sciences/Section of Neurosurgery, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH